Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.2c00384
Abstract: Selective degradation of the cyclin-dependent kinases 12 and 13 (CDK12/13) presents a novel therapeutic opportunity for triple-negative breast cancer (TNBC), but there is still a lack of dual CDK12/13 degraders. Here, we report the discovery… read more here.
Keywords: cdk12; highly potent; cdk12 cdk13; selective dual ... See more keywords
Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-0222
Abstract: Therapeutic perturbation of cyclin-dependent kinase 12 (CDK12) is proposed to have pleiotropic effects in ovarian cancer, including direct cytotoxicity against tumor cells and indirect induction of immunogenicity that confer synthetic sensitivity to immune-based treatment. However,… read more here.
Keywords: cdk13; cdk12 cdk13; ovarian cancer; tumor immune ... See more keywords